Business Wire

Dole, Employees Give to Restore and Rebuild Devastated Central America

1.6.2021 17:15:00 EEST | Business Wire | Press release

Share

On November 3, 2020 Hurricane Eta made landfall in Central America as a powerful Category 4 storm. Just two weeks later Hurricane Iota, a Category 5 storm followed nearly the same path through the region, unleashing heavy rains, winds, massive flooding and severe landslides, causing widespread destruction.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210601005255/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Replanting bananas in Honduras. Restoring fields and livelihoods destroyed by Hurricanes Eta and Iota in November 2020. (Photo: Business Wire)

Communities and towns in Honduras and Guatemala - many that support Dole farms and workers – were leveled in the wake. Though Dole was able to successfully evacuate its workers and families prior to the hurricanes’ arrivals, many others were not as fortunate and lost their lives or livelihoods, their possessions and their crops. In the aftermath, water was needed to drink, homes were in need of repair, and clothes, supplies and appliances in need of replacement.

As an organization closely connected to these communities through the banana industry, Dole swiftly moved to lend aid and resources. But not just the company as an entity stepped in, many Dole employees, partners, and public supporters —no matter how far physically from these communities — also contributed their own time and their own funds to help.

In these six months since the hurricanes’ devastation much has been accomplished.

  • Dole employees, the company and the public together raised, collected and donated a quarter of a million dollars to purchase food baskets of essential food items -- red beans, rice, corn flour, vegetable oil and powdered milk, capable of feeding a family of five for a month. These food baskets were distributed to 10,000 families in-need in communities surrounding our operations and through relief organizations CEPUDO and the Cortés Chamber of Commerce with established distribution networks in other areas.
  • The Red Cross of Honduras received donations of dozens of boxes of clothing and footwear contributed by Dole employees in North America and Dole’s Standard Fruit De Honduras. In addition to 500,000 Lempiras ($20,000US) to help those in need and provide support.
  • Dole provided use of company machinery and heavy equipment to repair public services, bridges, roads, and highways.
  • Dole allocated space on southbound vessels to humanitarian organizations importing and distributing disaster relief goods and equipment.
  • With many banana production areas completely destroyed, Dole, as a major employer of choice in the region, has expedited efforts to restore banana plantations to full production. Farm land preparation takes time and is completely tailored to the conditions of each agricultural area, yet returning jobs and paychecks to the areas quickly is critical.

“I cannot sufficiently convey the heartbreaking destruction these communities endured,” said Nelson Montoya President of Dole Fresh Fruit North America. “However, this catastrophe did not defeat them. The compassion, resiliency and camaraderie of all those on our team in Honduras and Guatemala has been inspiring to me. We will continue to invest in getting everyone back on their feet.”

The investment reached a significant milestone in the rehabilitation process in Honduras, with the first planting of new banana fields at Mendez Farm, Barimasa Zone on May 4, followed closely with planting at Copote Farm in the Isletas Zone and most recently the Palo Verde farm in the Coyoles Zone.

As the company works to restore production volumes derived from these devastated areas in Honduras and Guatemala, Dole expects customers will begin receiving Dole premium fruit from these regions in January 2022.

About Dole Food Company

Dole Food Company, Inc., is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education. For more information, please visit www.dole.com .

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

William Goldfield
818-874-4647
william.goldfield@dole.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye